SOURCE: MediJane Holdings Inc.

April 10, 2014 08:30 ET

MediJane Holdings Retains Peacock Meyers for IP and Trademark Protection

LONGMONT, CO--(Marketwired - Apr 10, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has retained the services of patent and intellectual property law firm Peacock Meyers, P.C. ("Peacock Meyers") to file all necessary and requisite documents with the United States Patent and Trademark Office (USPTO) to secure the trademark "MediJane" or any combination as it applies to the medical marijuana industry.

In addition, Peacock Meyers will also be responsible for all individual MediJane product trademarks, registrations, and possible patent filings and IP protection on current and future products.

"The protection of our intellectual property and trademarks will be very important as we expand and cultivate our brand identity and recognition as the Company grows," stated Ronald Lusk, CEO of MediJane Holdings Inc. "As a medical marijuana company and brand, it is our mission to maintain and ensure the highest levels of quality, consistency, and effectiveness of our products and delivery systems. We believe that the 'MediJane' name encompasses that brand vision by incorporating both traditional and emerging characteristics of the medical cannabis industry. Having a firm like Peacock Meyers guiding us with intellectual property issues can help to ensure the protection and longevity of our valuable brand."

Founded in 1995, Peacock Meyers, P.C. ( is a full-service intellectual property law firm based in New Mexico with offices in New York, Washington, D.C., and Tulsa, Oklahoma. Peacock Myers provides high quality intellectual property law services to all clients, from education and government entities to large and small businesses and individuals.

About MediJane Holdings Inc. (MJMD)

MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medicinal marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems. With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead product is an innovative non-drowsy "Daytime Pain plus CBD" oral capsule for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. This smokeless and accurate dose alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.

For more information, visit

Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.

Contact Information